An increase of 4.8-fold (5:1, E:T) in killing of CD19+ EL-4 cells as compared to unmodified CD19neg EL-4 (mouse T-cell lymphoma) targets demonstrated specificity for CD19 by CAR T cells. This evidence concerns the gene CD19 and T-cell non-Hodgkin lymphoma.